QuidelOrtho Corporation

Equities

QDEL

US2197981051

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX 17:58:52 09/05/2024 BST 5-day change 1st Jan Change
43.72 USD +2.45% Intraday chart for QuidelOrtho Corporation +3.98% -40.43%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
RBC Cuts Price Target on QuidelOrtho to $68 From $81, Keeps Outperform Rating MT
Transcript : QuidelOrtho Corporation, Q1 2024 Earnings Call, May 08, 2024
Earnings Flash (QDEL) QUIDELORTHO CORPORATION Posts Q1 Revenue $711M, vs. Street Est of $695.1M MT
Earnings Flash (QDEL) QUIDELORTHO CORPORATION Reports Q1 EPS $0.44, vs. Street Est of $0.40 MT
QuidelOrtho Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
QuidelOrtho Corporation Announces CEO Changes CI
QuidelOrtho Corporation Appoints Brian J. Blaser as President and to the Board CI
QuidelOrtho Shares Fall on Decision to Withdraw FDA 510(k) Submission for Savanna RVP4+ Assay MT
QuidelOrtho Gets US FDA Clearance For QuickVue COVID-19 Test MT
QuidelOrtho Corporation Receives FDA 510(K) Clearance for its QuickVue COVID-19 Test CI
QuidelOrtho Receives Canada's Approval for Triage PLGF Test to Detect Pregnancy Complications MT
Transcript : QuidelOrtho Corporation Presents at 45th Annual Raymond James Institutional Investors Conference 2024, Mar-05-2024 04:00 PM
Sector Update: Health Care Stocks Mixed Late Afternoon MT
Sector Update: Health Care MT
QuidelOrtho Shares Decline Following UBS Downgrade MT
UBS Downgrades QuidelOrtho to Sell From Neutral, Adjusts Price Target to $42 From $70 MT
Sector Update: Health Care Stocks Mixed in Late Afternoon MT
Sector Update: Health Care MT
QuidelOrtho Terminates CEO Douglas Bryant, Postpones Investor Day MT
QuidelOrtho Corporation Announces CEO Changes CI
QuidelOrtho Corporation Announces Changes in Executive Leadership, Effective from February 21, 2024 CI
Sector Update: Health Care Stocks Gain Late Afternoon MT
Sector Update: Health Care Stocks Rise in Afternoon Trading MT
Top Midday Decliners MT
QuidelOrtho Shares Slump After Analysts Downgrade Stock Following Lower Q4 Results MT
Chart QuidelOrtho Corporation
More charts
QuidelOrtho Corporation is engaged in vitro diagnostics, developing and manufacturing intelligent solutions. The Company sells its products directly to end users through a direct sales force and through a network of distributors, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, other point-of-care (POC) settings, blood banks and donor centers, as well as for individual, non-professional, over the counter (OTC) use. The Company provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics, Ortho Connect, Ortho Plus, Ortho Vision, QuickVue, Quidel, QuidelOrtho, QVue, Savanna, Sofia, Solana, Thyretain, Triage, Virena, Vitros among others. It provides support for its customers across more than 130 countries and territories.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
42.68 USD
Average target price
54.4 USD
Spread / Average Target
+27.46%
Consensus
  1. Stock Market
  2. Equities
  3. QDEL Stock
  4. News QuidelOrtho Corporation
  5. William Blair Downgrades QuidelOrtho to Market Perform From Outperform